Six-Minute Walk as a Measure of Walking Capacity and Endurance in Patients With Pediatric-Onset Multiple Sclerosis.
Journal
Neurology
ISSN: 1526-632X
Titre abrégé: Neurology
Pays: United States
ID NLM: 0401060
Informations de publication
Date de publication:
19 Aug 2022
19 Aug 2022
Historique:
received:
17
03
2022
accepted:
27
06
2022
entrez:
19
8
2022
pubmed:
20
8
2022
medline:
20
8
2022
Statut:
aheadofprint
Résumé
Despite low levels of disability, youth with pediatric-onset MS (POMS) engage in less physical activity compared to peers. The contribution of walking capacity, endurance, behavior, and MS co-morbidities remain relatively undefined and may provide valuable insights into the limitations toward physical activity in youth with MS. Investigate differences in walking capacity, endurance and real-world behaviors of daily activity between youth with POMS and controls. Forty-five POMS and 85 control subjects were enrolled. The POMS cohort had a mean age of 16.9±2.7 years with a mean disease duration of 2.8±2.6 years. A greater proportion of the POMS cohort was overweight/obese compared to controls (60% versus 33%). Subjects with MS walked a significantly shorter distance in 6 minutes compared to controls (1848 feet vs 2134 feet, p<0.0001) and, unlike controls, were unable to accelerate to their peak speed at the end of the 6MW. BMI category and MS disease significantly impacted 6MW performance. Using continuous accelerometry, subjects with MS spent less time in moderate-to-vigorous physical activity compared to controls (20.4 minutes/day vs 35.4 minutes/day, p=0.0003). The POMS cohort reported significantly higher levels of depression and fatigue, but self-reported similar levels of daily physical activity as controls. Youth with POMS exhibit slower 6MW performance and less daily engagement in moderate-to-vigorous physical activity, suggesting limitations in functional walking capacity, endurance, and daily activity behavior. Limitations in walking endurance and capacity are most prominent in those youth who are overweight/obese and living with MS. This study provides Class III evidence that, compared to healthy controls, patients with pediatric-onset MS walk shorter distances on the 6 minute walk test, are less able to accelerate to peak speed at the end of the test, and are less physically active.
Sections du résumé
BACKGROUND
BACKGROUND
Despite low levels of disability, youth with pediatric-onset MS (POMS) engage in less physical activity compared to peers. The contribution of walking capacity, endurance, behavior, and MS co-morbidities remain relatively undefined and may provide valuable insights into the limitations toward physical activity in youth with MS.
OBJECTIVE
OBJECTIVE
Investigate differences in walking capacity, endurance and real-world behaviors of daily activity between youth with POMS and controls.
RESULTS
RESULTS
Forty-five POMS and 85 control subjects were enrolled. The POMS cohort had a mean age of 16.9±2.7 years with a mean disease duration of 2.8±2.6 years. A greater proportion of the POMS cohort was overweight/obese compared to controls (60% versus 33%). Subjects with MS walked a significantly shorter distance in 6 minutes compared to controls (1848 feet vs 2134 feet, p<0.0001) and, unlike controls, were unable to accelerate to their peak speed at the end of the 6MW. BMI category and MS disease significantly impacted 6MW performance. Using continuous accelerometry, subjects with MS spent less time in moderate-to-vigorous physical activity compared to controls (20.4 minutes/day vs 35.4 minutes/day, p=0.0003). The POMS cohort reported significantly higher levels of depression and fatigue, but self-reported similar levels of daily physical activity as controls.
CONCLUSIONS
CONCLUSIONS
Youth with POMS exhibit slower 6MW performance and less daily engagement in moderate-to-vigorous physical activity, suggesting limitations in functional walking capacity, endurance, and daily activity behavior. Limitations in walking endurance and capacity are most prominent in those youth who are overweight/obese and living with MS.
CLASSIFICATION OF EVIDENCE
METHODS
This study provides Class III evidence that, compared to healthy controls, patients with pediatric-onset MS walk shorter distances on the 6 minute walk test, are less able to accelerate to peak speed at the end of the test, and are less physically active.
Identifiants
pubmed: 35985830
pii: WNL.0000000000201098
doi: 10.1212/WNL.0000000000201098
pmc: PMC9651457
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NINDS NIH HHS
ID : K23 NS116225
Pays : United States
Informations de copyright
© 2022 American Academy of Neurology.
Références
Neurology. 2015 Nov 10;85(19):1663-9
pubmed: 26268901
BMC Med Res Methodol. 2019 Apr 2;19(1):72
pubmed: 30940079
Mult Scler Relat Disord. 2014 Mar;3(2):186-93
pubmed: 25878006
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Med Sci Sports Exerc. 2003 Aug;35(8):1381-95
pubmed: 12900694
Front Neurol. 2021 Jul 26;12:698599
pubmed: 34381416
Obesity (Silver Spring). 2013 Mar;21(3):E236-43
pubmed: 23404845
J Pediatr. 2016 Dec;179:197-203.e2
pubmed: 27717498
Mult Scler. 2012 Jul;18(7):914-24
pubmed: 22740603
Gait Posture. 2018 Jan;59:211-216
pubmed: 29078135
Mult Scler. 2021 Sep;27(10):1597-1605
pubmed: 33245672
J Pediatr. 2017 Mar;182:204-209.e1
pubmed: 28087053
Mult Scler. 2012 Mar;18(3):329-34
pubmed: 21844064
J Child Neurol. 2013 Jun;28(6):713-8
pubmed: 22805247
Pediatr Pulmonol. 2006 Jul;41(7):618-22
pubmed: 16703573
PLoS One. 2018 Oct 15;13(10):e0205792
pubmed: 30321226
Neurology. 2019 Jun 11;92(24):e2764-e2773
pubmed: 31092624
Mult Scler Relat Disord. 2021 Apr;49:102795
pubmed: 33545667
PLoS One. 2014 Feb 26;9(2):e85741
pubmed: 24586244
Mult Scler. 2008 Apr;14(3):383-90
pubmed: 17942508
Nat Rev Rheumatol. 2017 May 23;13(6):368-379
pubmed: 28533552
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Mult Scler. 2009 Dec;15(12):1502-8
pubmed: 19965517
PLoS Curr. 2013 Jul 08;5:
pubmed: 23867975
J Pediatr. 2011 Mar;158(3):447-51
pubmed: 20884008
Br J Sports Med. 2018 Nov;52(22):1445-14563
pubmed: 29191931
BMC Pulm Med. 2021 Sep 21;21(1):297
pubmed: 34548058
Neurorehabil Neural Repair. 2016 May;30(4):373-83
pubmed: 26216790
BMC Neurol. 2012 Dec 27;12:161
pubmed: 23270547
JAMA. 2018 Nov 20;320(19):2020-2028
pubmed: 30418471
Mult Scler Relat Disord. 2019 Nov;36:101368
pubmed: 31557681
Muscle Nerve. 2010 Apr;41(4):500-10
pubmed: 19941337
Am J Respir Crit Care Med. 1998 Nov;158(5 Pt 1):1384-7
pubmed: 9817683
Dev Med Child Neurol. 2019 Nov;61(11):1289-1294
pubmed: 30950520
Neurology. 2020 Sep 29;95(13):e1844-e1853
pubmed: 32690790
Disabil Rehabil. 2005 Nov 30;27(22):1365-71
pubmed: 16372431
Int J Behav Nutr Phys Act. 2015 Feb 11;12:11
pubmed: 25881074
Physiother Can. 2011 Spring;63(2):166-80
pubmed: 22379256
Mult Scler Relat Disord. 2020 Jul;42:102026
pubmed: 32272443